Rigor Reviewed

Rigor-Reviewed Manuscript

Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.

Name: Αlpha¹ Rigor Record — Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
Item: Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
Rating: 96
Author: Αlpha¹

Pasqua MR, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 4 high issues for “Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 52 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Implausibly large reported effectAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized crossover trial with strong methodological rigor across most dimensions. The main weakness is the data and code availability, which is vague and conditional, and there are minor internal inconsistencies in the reported numbers that warrant correction.

Both reviewers agreed on study type (interventional) and on all dimension statuses except minor sub-criterion differences (outlier handling, data statement adequacy). The statistics verification component had limited coverage (0 tests recomputed), so statistical correctness is not fully verified. The copyedit and integrity checks flagged minor internal inconsistencies.

9 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

Prior work is cited extensively, including references on AID limitations (refs 5-7), obesity in T1D (refs 8-14), and semaglutide's glycemic/weight benefits in T2D (refs 16-18). The rationale linking semaglutide's potential to improve postprandial control and weight in T1D is clearly stated. Limitations of prior research (e.g., no clinical trials of semaglutide in T1D, only retrospective data) are acknowledged, and the study addresses this gap.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior work on automated insulin delivery limitations, obesity in T1D, and semaglutide's benefits in T2D, with a logical rationale linking these to the study objectives.

Evidence

paraphrase[Main, paragraph 1-2]

“However, in large randomized trials assessing AID use, 34–53% of participants were still not able to achieve an HbA1c of less than 7%... Semaglutide has demonstrated glycemic, weight and cardiac benefits in those with and without type 2 diabetes (T2D).”

direct quote[Main, paragraph 2]

“The aim of this study was to assess whether semaglutide, versus placebo, improves glycemic control and other nonglycemic outcomes in those with T1D while using AID.”